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Central hypoventilation syndromes (CHS) are rare diseases of central autonomic respiratory control associated with
autonomous nervous dysfunction. Severe central hypoventilation is the hallmark and the most life-threatening
feature. CHS is a group of not-fully defined disorders. Congenital CHS (CCHS) (ORPHA661) is clinically and genetically
well-characterized, with the disease-causing gene identified in 2003. CCHS presents at birth in most cases, and
associated with Hirschsprung’s disease (ORPHA99803) and neural crest tumours in 20% and 5% of cases, respectively.
The incidence of CCHS is estimated to be 1 of 200,000 live births in France, yet remains unknown for the rest of the
world. In contrast, late-onset CHS includes a group of not yet fully delineated diseases. Overlap with CCHS is likely, as
a subset of patients harbours PHOX2B mutations. Another subset of patients present with associated hypothalamic
dysfunction. The number of these patients is unknown (less than 60 cases reported worldwide). Treatment of CHS is
palliative using advanced techniques of ventilation support during lifetime. Research is ongoing to better understand
physiopathological mechanisms and identify potential treatment pathways.
The Fourth International Conference on Central Hypoventilation was organised in Warsaw, Poland, April 13–15, 2012,
under the patronage of the European Agency for Health and Consumers and Public Health European Agency of
European Community. The conference provided a state-of-the-art update of knowledge on all the genetic, molecular,
cellular, and clinical aspects of these rare diseases.
Keywords: Central hypoventilation, Autonomic nervous system, Congenital central hypoventilation syndrome, PHOX2B
gene, Hirschsprung’s disease, Alanine expansion, Central control of breathing, Home mechanical ventilation, Phrenic
nerve stimulation, Diaphragmatic stimulationIntroduction
The Fourth International Conference on Primary Central
Hypoventilation, SCIENCE & LIFE OF CHS, was held in
Warsaw, Poland, April 13–15, 2012. The meeting was
under the patronage of the European Agency for Health
and Consumers (EAHC) and Public Health European
Agency (PHEA) of European Community. It was organised
by the European CHS Consortium.
The conference aimed to provide an update of knowledge
recently acquired on : i) functional, molecular and genetic* Correspondence: ha.trang@rdb.aphp.fr
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unless otherwise stated.aspects of central control of breathing, of Autonomic
Nervous System Dysfunction and of Central Hypoventilation
Syndromes (CHS) (ORPHA661); ii) on epidemiology,
diagnosis, ongoing care management, health care standards
of and service organization for CHS. The conference also
provided an understanding of the current state of CHS care
across the world and an opportunity to exchange ideas to
improve service and care organisation in the future.What we know and what we don’t know: The unknowns
are yet to surface
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http://www.ojrd.com/content/9/1/194Central hypoventilation syndromes (CHS) are rare
disorders of central autonomic respiratory control and
global dysfunction of the autonomic nervous system. These
result in alveolar hypoventilation during spontaneous
breathing or ventilatory dependency with the absence
or reduction of a response to CO2. CHS include a hetero-
geneous group of not fully characterized diseases.
Congenital CHS (CCHS) is a clinically and genetically
well-characterized disease. In contrast, late-onset CHS
includes a group of not yet fully delineated diseases.
Overlap with CCHS is likely, as a subset of patients
harbours Paired-like homeobox 2b (PHOX2B) mutations.
Another subset of patients present with associated
hypothalamic dysfunction. Ventilation support using
advanced techniques is required for life. Large disparities
exist in access to diagnosis and treatment across Europe.
The long-term outcomes are unknown.
Respiration and the respiratory system are under
two main control systems: the cortex which provides
voluntary or behavioural control, and the bulbo-pontine
in the brain stem which provides autonomic or chemical
control.
In his very first hours of life, a baby with CCHS
becomes cyanotic with severe desaturation. He breathes
very slowly and superficially, may present with apnoeas,
but makes no effort to breathe. Rapidly, intubation and
ventilation are required. Polysomnographic recordings
show slow and shallow breathing, with a reduction in the
respiratory rate and the amplitude of ventilation. This
results in alveolar hypoventilation, desaturation and
hypercapnia. These features are more marked in sleep
than in wakefulness and during non-Rapid Eye Movement
(non-REM) sleep than in REM sleep [1-3]. As a matter of
fact, non-REM sleep is a stage in sleep which is almost
entirely under chemical control. Nevertheless, the absence
or reduction of ventilatory response to CO2 is present,
whatever the state of alertness.
In 2003, the discovery of PHOX2B mutations in CCHS
patients was a major step forward in our understanding
of the disease [4,5]. By extending our knowledge
through basic research, molecular, cellular, and animal
studies, it is now known that the PHOX2B gene controls
neuron differentiation very early during pregnancy, and
the brainstem retro-trapezoid nucleus (RTN) in which
PHOX2B is expressed is found to be crucial in control of
breathing [6,7].
However, does PHOX2B mutation wholly account for the
manifestation of CCHS? Are RTN cells the only neuronal
cells underlying these respiratory deficits? Investigations
using new-born mice carrying the PHOX2B mutation are
providing new insights into neuronal involvement in
CCHS [8,9]. The mutant animals have a similar phenotype
to humans and present with apnoeas and reduced
hypercapnic ventilatory responses.CCHS is associated with major conditions such as
Hirschsprung’s disease and neural crest tumours [10-12].
Is there a genetic link underlying these conditions?
During the conference, outstanding experts will highlight
on how PHOX2B may interact with the genetic codes from
these diseases, to produce the major CCHS phenotypes.
An update will be made on PHOX2B anomalies, sessions
on inheritance and penetrance, genetic counselling and
future potential treatments.
Diagnosis and management of CCHS remains prob-
lematic, especially as new presentations of the condition
emerge. Milder forms of disease have been observed in
babies who at birth present with apnoeas and desaturation,
only to improve within weeks and in some cases do not
require ventilatory support. On genetic testing, these indi-
viduals are shown to have a +5 alanine expansion, and on
monitoring sleep parameters have all the features of CCHS:
sleep desaturation, and increased tidal CO2 to 59 mmHg
max, averaging around 54–55 mmHg. Genetic studies of a
family revealed that the mother had a +5 alanine expansion,
but no clinical symptoms, and the father had no PHOX2B
abnormalities. These new presentations raise diagnostic
and management issues and questions relating to the
categorisation of the disease.
There are many more management issues to confront
us including the appropriate mode of ventilation support
for patients, and whether specific criteria apply to cardiac
pacing in CCHS patients compared with the general
population. Can follow-up and care be tailored to each
patient? What are the best clinical pathways for transition
from paediatric to adult care?
At present, there is a paucity of information on the
location of CHS patients, the mortality rate and the
incidence of CCHS, currently estimated at one in 200
000 births [13]. It is most likely that the incidence of
CCHS is much higher. Also, other questions need to
be addressed such as, where the experts in CHS are,
how CHS is diagnosed or managed in each country,
and what guidelines for diagnosis, treatment, and for
carers are used. A consensus is required on information
for families and carers.
To address these issues, the European CHS Project was
initiated by the EUCHS Consortium. It is co-financed by
the EAHC, an official agency of the European Community,
and six national public institutions from France, Germany,
Italy, Poland, Sweden and United Kingdom. The project
includes altogether 11 European countries (Spain, Portugal,
Austria, Slovenia, and Croatia) that account for 70% of EU
population. This is a three-year project with a 6-month
extension. The objective of the project is to develop a
secure web-based CHS registry to describe the demograph-
ics of the condition, medical practice in Europe, and serve
as a database for research and health policy decisions. In
addition, a guideline for diagnosis and treatment of CHS,
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will be produced. Expert centres will be identified,
existing service for CHS in Europe will be evaluated and
a multilingual website set up to facilitate communication
between patients and healthcare professionals.
The secure web CHS registry is the first site to gather
population-based data and has been operating for a year.
Emerging data is providing an insight into the expert
centres in Europe which can now be identified on an
interactive map on the web site. The European guidelines,
developed by EUCHS for CHS, are targeted at healthcare
professionals and the first draft is currently under review,
before publication. The patient and carer information
booklet, in multi-lingual formats, are available on the
website. This 4th International Conference on Central
Hypoventilation is organised as part of the EUCHS
Project to gather and exchange knowledge between health-
care professionals, families, researchers and clinicians.
Neuronal lesions underlying the respiratory defects of CCHS
Jean-François BRUNET, PhD. IBENS, CNRS 8197, INSERM
1024, École normale supérieure, Paris, France
CCHS is a complex dysautonomia with variable
genetic penetrance [12]. The majority of CCHS symptoms
and associated conditions, such as neuroblastoma and
Hirschsprung’s disease, arise from the dysfunction of the
visceral nervous system [11,12]. For this reason, the
pan-visceral homeobox transcription factor PHOX2B was
originally tested as a candidate gene and later confirmed
as the causative gene in CCHS [4,5].
PHOX2B is expressed in a limited set of neuronal
circuits during embryonic development and throughout
adult life. These circuits are all related in that they regulate
vital functions: cardiovascular, digestive and respiratory.
The majority of PHOX2B neurons are in the motor and
sensory branches of these circuits. In the sensory pathway,
PHOX2B is expressed in three cranial sensory ganglia: gen-
iculate, petrosal, nodose, which monitor vital parameters
such as blood pressure, the chemical composition of the
blood and digestive contents. It is also expressed in
the nucleus of the solitary tract (nTS) where this informa-
tion is integrated and fed back continuously to the
PHOX2B-expressing autonomic ganglia (parasympathetic,
sympathetic and enteric), through their preganglionic
neurons in the central nervous system [14]. In PHOX2b
knockout mice, all these neurons are absent, indicating
that PHOX2B is essential for the development and
function of nerve cells within this system.
The defining symptom of CCHS is respiratory: hypo-
ventilation with apneic episodes, usually during sleep. The
disorder ranges from potentially lethal respiratory distress
at birth to late-onset respiratory arrests, and is accompanied
by the absence of hyperventilation in response to hypercap-
nic challenge [10].In the circuits that control breathing, PHOX2B is
expressed and required in the nodose ganglion which
contains the neurons responsible for the pulmonary
stretch or Herring-Breuer reflex, in the carotid body
(CB) which contains oxygen and CO2 sensors, in the
petrosal ganglion that innervates the CB, and in the nTS
that integrates all this mechano-, chemo- and barosensory
information. PHOX2B is also expressed and required in
several noradrenergic centres, such as the locus ceruleus
and A5, which modulate respiratory rhythm. It is also a
determinant of branchial motor neurons (for example in
the facial motor nucleus and the nucleus ambiguous),
which are the respiratory motoneurons in the aquatic
ancestors of air-breathing vertebrates (including humans),
in whom they have kept a minor role in breathing. Thus,
the known sites of action of PHOX2B, while revealing
a strong implication in breathing, do not readily explain
the respiratory symptoms of CCHS, and suggest the
involvement of other neurons. As it turns out, PHOX2B is
also expressed in interneurons in the hindbrain whose
function is unknown and might explain these respiratory
symptoms.
To model CCHS in animals, one of the most common
CCHS-causing mutations, a +7 alanine expansion of
the PHOX2B gene, was introduced into mice. Mice
harboring this mutation died at birth of respiratory
failure [15]. Plethysmographic analysis performed prior to
death revealed an absence of chemoreflex response to
hypercapnia. Histological analysis showed a massive
loss of PHOX2B-expressing, glutamatergic (Vglut2+),
neurokinin-1 receptor-positive neurons that form the
RTN, located at the surface of the ventrolateral medulla
below the facial motor nucleus.
In anaesthetized rats, RTN was previously shown to be
sensitive to blood levels of CO2 [16]. Electrophysiological
data also showed that RTN PHOX2B+ neurons establish
excitatory glutamatergic synapses with the pre-Bötzinger
complex, the respiratory pacemaker, to accelerate respira-
tory rhythm at birth. If the RTN is substantially deficient or
absent, as in knock-in mice carrying a +7 alanine
expansion of the PHOX2B gene, the animals die at birth
from respiratory failure.
RTN Phox2b+ neurons express the basic-helix-loop-helix
(bHLH) transcription factor, “atonal homolog 1” (Atoh1)
(also expressed around embryonic day 12.5 in proliferating
rhombic lip progenitors with no role in respiration
described to date). Tracking of post-mitotic neurons of
the RTN that express Atoh1 revealed that they migrate
with the facial nucleus (but do not require its presence
to do so). The expression of Atoh1 in the RTN region
is abolished in mice carrying a +7 alanine expansion
mutation in PHOX2B. This marker thus allows us to
follow the fate of RTN neurons conditional PHOX2B
mutations, as exemplified below.
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embryonic neuronal precursors with a history of expres-
sion of two other transcription factors: Early Growth
Response Protein 2 (Egr2) and Ladybird homeobox 1
(Lbx1), as demonstrated by genetic tracing studies in
mice, using either a Lbx1::Cre, or a Egr2::Cre allele, com-
bined with a β-galactosidase reporter gene. Crossing the
Lbx1::Cre or the Egr2::Cre allele with a floxed PHOX2B
allele (i.e. conditional null allele) to produce Phox2b lox/lox;
Egr2 cre/+ or Phox2b lox/lox;Lbx1 cre/+ genetic backgrounds,
thus allows to destroy the RTN while affecting much fewer
neurons than in Phox2b27ala mutants (where the deleteri-
ous mutation is expressed in all Phox2b+ neurons) .
In vitro experiments have compared the rhythmic,
respiratory-like activity of the hindbrain-spinal cord from
mice embryos at E14 in wild type and PHOX2B mutant
backgrounds (Phox2b 27ala, Phox2b lox/lox; Egr2cre/+ and
Phox2b lox/lox; Lbx1 cre/+). Optical recordings of calcium
uptake (a measure of rhythmic activity) at pH 7.4 and
pH 7.2 (a proxy for hypercapnic challenge) showed a
rhythmic activity in the RTN region at pH 7.4 and an ac-
celeration of this activity at pH 7.2 in control animals. In
contrast, there was no rhythmic activity at either pH in
the RTN region of +7 alanine PHOX2B expansion and
conditional PHOX2B mutants, showing the functional ab-
sence of a RTN. This finding was confirmed in electro-
physiological recordings of the phrenic nerve at E16,
where rhythmic activity is normally accelerated at an
acidic pH, but not in the +7 alanine PHOX2B mutant or
the conditional knockouts, showing that entrainment by
the CO2-sensitive RTN of the respiratory pacemaker (the
pre-Bötzinger complex) does not occur [17].
A mutation even more selective for the RTN was then
engineered, which consists in pairing a conditional +7
alanine PHOX2B allele with the Egr::Cre or a Lbx1::Cre
allele: this combination most likely spares many neurons
affected in the conditional nulls (Phox2b lox/lox; Egr2 cre/+
or Phox2b lox/lox; Lbx1 cre/+ mutants), since the majority
of neurons that depend on PHOX2B are not sensitive to
the +7 alanine mutation. In these mutant backgrounds,
the RTN was histologically and functionally abolished, as
in the previous PHOX2B mutants analyzed, strengthen-
ing the case for the RTN as the chemoreflex center.
However, unlike the conditional nulls, the animals sur-
vived [8].
This unexpected outcome shows that the central che-
moreflex, long considered as the paramount drive to
breathe, is not required in mice for survival. It suggests
that there are one or more other Phox2b-positive (and
Phox2b27ala-sensitive) populations of neurons which, ei-
ther by themselves or in combination with the deletion of
the RTN and consequent lack of chemoreflex, cause re-
spiratory arrest at birth, in mice and possibly also in
humans. Our focus is now on the quest for this populationof neurons that, in combination with the RTN, might ex-
plain the full respiratory phenotype of CCHS.
PHOX2B and midkine/Alk signalling in the control of
sympathetic neuron proliferation and neuroblastoma
predisposition
Hermann ROHRER. Research Group Developmental
Neurobiology, Department of Neurochemistry, Max
Planck Institute for Brain Research, Frankfurt am Main,
Germany
Development neurobiologists study the generation of
neurons from progenitors and the mechanisms that con-
trol their specification and differentiation. This approach
has been used to follow the fate of specific groups of
neurons in the autonomic nervous system and to inves-
tigate the molecular mechanisms that predispose neuro-
blasts to develop neuroblastoma, a tumour arising in
sympathetic ganglia and the adrenal medulla.
Neurons and glial cells of the peripheral nervous sys-
tem differentiate from precursor cells of the neural crest.
Neuronal development is controlled by a network of
transcription factors including PHOX2B, ASCL1, GATA3
and HAND2 [18]. They control distinct cell functions,
such as differentiation, migration, proliferation and sur-
vival in both the embryonic and adult peripheral nervous
system.
During neurogenesis, undifferentiated precursor cells
divide asymmetrically to produce both a precursor cell
that remains undifferentiated and a neuron progenitor
cell that differentiates to a post-mitotic neuron. In con-
trast to this canonical pattern of neurogenesis found
throughout the nervous system, in sympathetic ganglia,
neuronal cells continue to divide after acquisition of neur-
onal properties. Differentiation of sympathetic neuron pre-
cursors is, therefore, not linked to cell cycle withdrawal.
This raises the suspicion that neurogenesis is less well
controlled in the sympathetic lineage compared to other
cells of the autonomic nervous system, and may lead to
tumours, such as, neuroblastoma [19].
Neuroblastoma arises from developing embryonic sym-
pathetic neurons, and is the most frequent extra-cranial
solid tumour in children, accounting for 10 per cent of all
childhood tumours. It has a broad clinical spectrum ran-
ging from benign tumours that spontaneously regress to
aggressive tumours that metastasize to the bone. Around
40% of tumours are aggressive, for which there is no treat-
ment. Mutations in PHOX2B gene and anaplastic lymph-
oma kinase (Alk) have been identified in both familial and
sporadic cases of the neuroblastoma [20].
The proliferation and differentiation of immature neuro-
blasts has been studied in response to wild type and mu-
tant PHOX2B proteins ectopically expressed in cultures of
chick and embryonic sympathetic neurons. PHOX2B vari-
ants with point mutations in the homeodomain were used.
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effects in sympathetic neuroblasts, which is lost in mutant
variants. The PHOX2B wild type may therefore act as a
tumour suppressor gene which is de-repressed by PHOX2B
mutations in the homeodomain. Alternatively, the mutant
proteins may affect a gain-of-function. To test this hypoth-
esis, the experiment was repeated after knockdown of en-
dogenous PHOX2B using siRNA, to mimic the situation of
a heterozygous PHOX2B mutation in neuroblastoma.
Under these conditions, PHOX2B variants with mutations
in the homeodomain increase the proliferation of imma-
ture sympathetic neurons. The increased proliferation is
blocked by HAND2 knockdown and restored by over ex-
pression of HAND2. HAND2 was precipitated from sym-
pathetic neuron not only with the wild type but also with
the PHOX2B mutant variants. Complexes of HAND2/
wild type PHOX2B appear to inhibit proliferation, while
complexes of HAND2/mutant PHOX2B have a prolifera-
tive effect on immature sympathetic neurones [21].
Neuroblastoma predisposition may be caused by a
deleterious gain-of-function which results in increased
proliferation of sympathetic neurons, since sympathetic
neural proliferation is controlled by the interaction of
HAND2 and PHOX2B. The differential effects of PHOX2B
mutations in the sympathetic and parasympathetic ganglia
may, in part, be explained by different regulatory mecha-
nisms and, specifically the role of HAND2. PHOX2B mu-
tation variants have different functional consequences
depending interaction with other mediators, expression
levels or post-inscriptional modifications. PHOX2B when
highly expressed may either affect proliferation during
neural development or, may cause the cell’s exit from the
mitotic cycle. Similar conclusions have been reached from
studies of the transcription factor, STL1, which binds not
only to promoters of neural differentiation but also to pro-
moters controlling cell proliferation.
Alk is a trans-membrane receptor tyrosine kinase and
predisposing Alk germline mutations are found in famil-
iar forms of neuroblastoma, and also in 8% of sporadic
neuroblastoma. The effect of Alk mutations have been
investigated in immature chick sympathetic neurons. Forced
expression of wild-type Alk and neuroblastoma-related
constitutively active Alk mutants in cultures of proliferat-
ing immature sympathetic neurons increased proliferation
of these cells, whereas pharmacological Alk inhibitors,
overexpressed Alk and, knockout Alk mutations decreased
proliferation [22].
Midkine, which is highly expressed in sympathetic gan-
glion has been identified as a ligand for the Alk receptor.
In cultures of proliferating immature chick sympathetic
neurons, Midkine-Alk signalling is essential and sufficient
to stimulate sympathetic neuron proliferation. In vivo in-
hibition of Alk-midkine signalling by virus-mediated siRNA
knockout of Alk and midkine leads to the formation ofsmaller sympathetic ganglia and reduced proliferation of
both tyrosine hydroxylase- and PHOX2B-positive cells,
confirming the role of midkine-Alk signalling in sympa-
thetic neuron proliferation. Stimulation of midkine-Alk
receptor signalling increases the expression of nMyc and
trkB - two genes which are associated with aggressive
forms of neuroblastoma [22].
Midkine-Alk signalling is specific to sympathetic gan-
glia. It regulates HAND2 mediated cell proliferation and
ganglion size by an auto regulatory mechanism. Increased
Nmyc expression may cause elevated and sustained Alk-
signalling leading to a predisposition to neuroblastoma
[22]. Both PHOX2B and Alk mutations may increase and
prolong proliferation of embryonic sympathetic neurones
in mouse models, increasing the probability of additional
mutations within this cell lineage, leading to the clinical
manifestation of neuroblastoma. Attempts to prove this
hypothesis are currently being undertaken.
CCHS: lessons from newborn mice
Jorge GALLEGO, PhD. Inserm U676, Robert Debré Uni-
versity Hospital, Paris, France
Mice are the preferred animal model for genetic studies.
As CCHS occurs in newborns, studies were undertaken in
neonatal mice. Three mutant mice models, were developed
which survived the early postnatal period: knock-out mice
with one invalidated allele of PHOX2B (PHOX2B +/−)
which allowed the study of postnatal respiratory breathing
and related functions such as thermoregulation; a con-
stitutional +7 alanine PHOX2B expansion mutation
(PHOX2B27Ala) that die within a few hours following
birth and, a conditional mutant PHOX2B27Ala in which
the mutation was confined to the RTN.
In all these studies, breathing variables, heart rate, body
temperature and markers of behavioural activity were mea-
sured non-invasively in neonatal mutant mice, by whole-
body flow barometric plethysmography, under baseline
conditions and, during exposure to chemical (hypoxia and
hypercapnia) and thermal stimuli. All parameters were
measured in mice during quiet sleep.
PHOX2b knockout mice
Null PHOX2b−/− mice die in utero but mice carrying one
invalidated PHOX2b allele (PHOX2b+/−) survive and are
fertile, and thus do not reproduce the CCHS phenotype [9].
The ventilatory response to hypercapnia in unrestrained
PHOX2b+/− newborn mice was about 40% smaller in
PHOX2b+/− than PHOX2b+/+ pups. CO2-sensitive sites
such as the locus coeruleus and area postrema, the RTN,
and afferent pathways from the carotid bodies (which
contribute to CO2 sensitivity) depend on PHOX2b for
their development. The postnatal impairment of the hy-
percapnic ventilatory response seen in PHOX2b+/− pups
resolved before 10 days of postnatal age. Importantly,
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on ambient temperature. Around thermoneutrality, the
hypercapnic ventilatory response increased with ambi-
ent temperature, although it was still lower in mutant
than in wild-type pups. However, the difference between
the absolute increase in ventilation in mutant and wild-
type pups become more pronounced as the temperature
increased above 29°C. At lower ambient temperatures
(26°C), the cold-induced depression of the ventilatory
response to hypercapnia was less pronounced in mutant
pups. Thus, the PHOX2b mutation affected not only the
control of breathing, but also the interaction of breathing
with thermoregulation. In 2-day-old PHOX2b+/− pups, the
immediate hyperpneic response to hypoxia was normal
but the hypoxic decline was markedly increased. The ven-
tilatory decrease caused by hyperoxia was larger in new-
born PHOX2b+/− mutant mice than in their wild-type
littermates and was magnified by longer apnea durations,
which suggested stronger tonic activity of oxygen-sensitive
peripheral or central chemoreceptors. Sleep apnoea time
was increased about 6-fold in 5-day old PHOX2b+/− mu-
tant pups and ventilation during active sleep was de-
creased by about 20%, compared to wild-type pups. Thus,
heterozygous Phox2b invalidation produced respiratory
phenotypes that differed markedly from CCHS.
Constitutive PHOX2b 27Ala/+ mice
Mouse models of CCHS were obtained using a knock-in
approach to introduce a +7 alanine expansion of the 20-
residue polyalanine tract (the PHOX2b27Ala allele) [15].
The heterozygous PHOX2b 27Ala/+ offspring of chimeric
founders were cyanotic soon after birth and died within
a few hours. During the first 20 min after delivery, the
breathing pattern ranged from gasping or very unstable
breathing interrupted by apnoeas to relatively shallow
breathing at a slower rate compared to wild-type litter-
mates. Apneic episodes were more frequent and lasted
longer in the mutants compared to the wild-type pups.
Importantly, the mutant pups had no response to hyper-
capnia. Thus, PHOX2b 27Ala/+ mice reproduced two
characteristic symptoms of human neonates with CCHS:
blunted or unstable breathing with apnoeas, and absence
of a ventilatory response to hypercapnia. Neuroana-
tomical studies of PHOX2b 27Ala/+ mice revealed that
the RTN/pFRG precursors degenerated or failed to dif-
ferentiate as early as embryonic day 12.5, whereas the
pre-Bötzinger complex was functional in embryos.
Conditional PHOX2b 27Ala/+ mice
A crucial issue regarding CCHS is whether genetic RTN
deletion and the associated loss of chemosensitivity in
PHOX2b 27Ala/+ pups accounts fully for their lethality at
birth. The answer is negative, as shown by a second mutant
mouse model in which PHOX2b 27Ala is specifically targetedto the RTN [8]. Although the Egr2cre/+; PHOX2b27Ala/+
mouse mutants lacked the RTN and their breathing was not
stimulated by CO2 elevation, they survived to adulthood.
Despite the absence of a normal CO2 response, PCO2 in the
blood was within the normal range and perinatal mortality
was very low. At 3 weeks of age, the mutants had normal
baseline ventilation in room air but increased their ventila-
tion only slightly in response to hypercapnia, to 20% of the
control value. At 4 months, adult mutants had significant
but incomplete recovery of the ventilatory response to
hypercapnia (to 40% of the control value). The mutants
showed vigorous and sustained minute-ventilation in-
creases in response to hypoxia, indicating the presence
of functional peripheral chemoreceptors. Furthermore,
when exposed to 100% O2, all mutants had periodic breath-
ing with long apneic pauses, indicating greater dependence
on tonic peripheral chemoreceptor function to maintain a
normal respiratory pattern.
Neither the RTN nor CO2 chemosensitivity is required
for life-sustaining breathing, yet constitutive PHOX2b27Ala/+
pups die soon after birth. Thus, defects in other PHOX2b +
neurons of the reticular formation may contribute to
the lethal breathing disorder at birth in these pups.
Taken together, the fact that genetic elimination of the
RTN severely abolishes CO2 sensitivity in constitutive
and conditional PHOX2b27Ala/+ mice supports a role for
a similar mechanism in the CO2 insensitivity that char-
acterizes CCHS. However, the survival and functional
breathing in conditional PHOX2b27Ala/+ mice also sug-
gest that the neurological basis for CCHS is not confined
to absence of the RTN and that compensatory mecha-
nisms partially restore CO2 sensitivity.
Overview of CCHS and PHOX2B mutations
Jeanne AMIEL. MD, PhD. Necker-Enfants Malades Uni-
versity Hospital, French Centre of reference for central
hypoventilation, Paris, France
CCHS is a rare disorder of the autonomic nervous sys-
tem with an estimated incidence of about 1 in 200,000
live births [13]. CCHS is characterised by central
hypoventilation and the absence of a chemoreflex to
CO2. It classically manifests in newborn babies. Isolated
central hypoventilation can occur later in life, childhood
to adulthood. This manifests as nocturnal alveolar
hypoventilation with mild autonomic nervous system dys-
function [23]. CCHS can be associated with neurocristo-
pathies, such as Hirschsprung's disease (16% of the cases)
[13] and neuroblastoma (5-10% of the cases [24,25].
Neuroblastoma is the most frequent extra-cerebral solid
tumour in children [26]. Hirschsprung's disease (HSCR) is
a malformation of the enteric nervous system which leads
to intestinal occlusion. The incidence of isolated HSCR is
of 1 in 5,000 live births and the major disease-causing
gene is the RET proto-oncogene [27].
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reports of the condition in monozygotic twins and in the
offspring of a woman with CCHS suggested a genetically
determined and possibly monogenic condition [28,29].
PHOX2B was subsequently identified as the disease
causing gene in CCHS and some cases of late onset CHS
[4,5,24,30]. Importantly, no PHOX2B gene mutations are
found in patients with sudden death syndrome or hy-
poventilation associated with hypothalamic dysfunction.
PHOX2B encodes a paired box homeodomain tran-
scription factor, characterized by two polyalanine repeats
of 9 and 20 residues in the C-terminal region. Heterozy-
gous in-frame duplications leading to alanine expansion
within the normal 20-alanine stretch from +5 to +13 al-
anines are the most frequent mutations (92%). Other
mutations are frameshift mutations leading to aberrant
C-terminal region, nonsense mutations and missense
mutations within the homeodomain [4,5,12]. In control
subjects alanine contractions (−5, −7 and −13 alanines)
in the 20-alanine stretch can be observed with no pheno-
typic consequences reported to date.
In most case the mutation arose de novo in the index
case. However, 15 to 20% of unaffected parents show som-
atic mosaicism for the mutation identified in the child [5].
Mosaic mutations arise from errors during mitotic divi-
sions. When a parent is a mosaic the recurrence risk can
be as high as 50% and depends on the degree of mosai-
cism in germ cells. As a germ line mosaicism cannot be
ruled out, parents with no somatic mosaicism detected are
counseled at 1% recurrence risk in siblings [31]. An adult
with CCHS has a 50% risk of transmitting the mutation to
the offspring. Pregnancies of CCHS female reported to
date were normal and babies were born around term.
Among alanine expansions, the shortest (i.e. +5 alanine
expansion) is incompletely penetrant for the ventilatory
phenotype and individuals may develop late-onset central
hypoventilation or no symptoms at all. They do not
present Hirschsprung's disease or neuroblastoma. Asymp-
tomatic cases harbouring a +5 alanine expansion are at
risk of acute ventilatory decompensation during anaesthe-
sia, respiratory infections or some therapies. They, and
their doctors, have to be informed of these risks [4,24,30].
From alanine expansions of +6 and above, the ventila-
tory phenotype is fully penetrant and will lead to CCHS.
Individuals with the +6 genotype have a moderate risk
and those with +7 or more alanine expansion are at great-
est risk for Hirschsprung’s disease. Neuroblastoma rarely
occurs in patients with alanine expansions. To date, there
is only one report of neuroblastoma which occurred in a
patient with a +13 alanine expansion mutation [24].
Around 8% of patients with the CCHS phenotype have
heterozygous PHOX2B gene mutations that do not lead
to alanine expansion but frameshift, nonsense or missense
[4,5,12,24,30]. These patients are at high risk of developingneuroblastoma and Hirschsprung’s disease. Frameshift
mutations can lead to either a +1 nucleotide or a +2
nucleotides frame. Mutations with +1 nucleotide frame-
shift, with and without 20-alanine expansion, have a lon-
ger protein, while +2 nucleotide mutations have a shorter
protein.
The capacity of PHOX2B mutant proteins to transacti-
vate the dopamine beta-hydroxylase promoter, a known
target for PHOX2B protein, has been investigated in vitro.
In the luciferase assay, the potential of PHOX2B proteins
with alanine expansions to transactivate the dopamine
beta-hydroxylase promoter declines with increasing length
of the polyalanine stretch from +6 alanine expansion while
the one of the +5 alanine expansion is similar to controls.
Transfection of PHOX2B wild-type and mutant con-
structs in HeLa cellsa shows that mutant PHOX2B pro-
teins (≥ + 9 alanine expansion) aggregate in the cytoplasm,
which abrogates their mobility and function in the nucleus.
In gel filtration studies of in vitro translated proteins, wild
type proteins form dimers, > + 5 alanine expansion pro-
teins form oligomers while +5 alanine expansion proteins
may oscillate between dimeric and oligomeric forms [11]
CCHS mutant proteins, therefore, like polyQ proteins tend
to misfold. This may explain the loss of transactivation of
the dopamine beta-hydroxylase promoter.
The ability of proteins to refold after misfolding was
investigated by fluorescence recovery after photo-bleaching
(FRAP) of cells transfected with either wild type or mutant
fluorescent tagged PHOX2B constructs. The time of re-
covery was delayed for mutant proteins and was related
to the length of the alanine expansion mutations. The
longer the alanine expansion the more misfolded and
reduced mobility of the PHOX2B mutant protein within
the cell. FRAP could be a reliable method for screening
drugs that have the ability to refold proteins, and provide
a new therapeutic approach to pharmacological treatment
of CCHS.
Misfolding can lead to aggregation of proteins. Both
processes activate intracellular chaperone proteins such
as, heat shock proteins which assist in folding and refold-
ing of proteins and, in preventing protein aggregation.
Indeed, chaperone proteins co-localize with aggregates
of PHOX2B proteins. Treatment of transfected cells with
mutant constructs and the antibiotic geldanamycin, an
enhancer of heat shock proteins, increases the mobility
of the mutant proteins, and further translocation to the
nucleus [32]. Misfolding of PHOX2b proteins may ex-
plain the loss of transactivation potential of mutant proteins.
Like alanine expansion, shorten or elongated PHOX2B mu-
tant proteins abolish or severely reduce the transactivation
of the dopamine beta-hydroxylase promoter and oligomerise
even in the absence of a normal 20-alanine tract.
The misfolding of mutant PHOX2B protein is not the
only mechanism leading to dysfunction of the ventilatory
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in a CCHS patient has led to the production of an N-
terminally truncated protein, by re-initiation of translation,
which did not form oligomers. The shortened protein was
located in the nucleus and e transactivation of the dopa-
mine beta-hydroxylase promoter was similar to controls
[33]. The mechanism by which this mutant protein leads
to ventilatory dysfunction is unknown.
Complete deletion of the PHOX2B gene is a rare event
which has been observed in a patient with Hirschsprung's
disease and in three families with CCHS [34]. Thus, as
heterozygous loss of PHOX2B function leads to variable
phenotypes, the role of modifier genes is highly likely.
This is also true for alanine expansion and frameshift muta-
tions. Note that no PHOX2B gene mutations are found in
patients with sudden death syndrome [35-37] or hypo-
ventilation associated with hypothalamic dysfunction [38].
PHOX2B mutations may trigger a wide range of auto-
nomic nervous system disorders, ranging from congenital
malformation to tumour predisposition. Some genotype-
phenotype correlations are currently used by practitioners
for counselling patients and their families. However, these
phenotype-genotype correlations are incomplete and the
molecular mechanisms underlying phenotypic variability
are still poorly understood. Protein misfolding and oligo-
merisation occur in the vast majority of PHOX2B muta-
tions, either alanine expansion or frameshift mutations.
The CCHS phenotype cannot be explained purely by a
loss of PHOX2B function.
Germline mosaicism and de novo PHOX2B mutations in
CCHS: implications for penetrance and inheritance
Tiziana BACHETTI, PhD. Laboratorio di Genetica
Molecolare, Istituto Giannina Gaslini, Genova, Italy
Genetic testing has confirmed the presence of PHOX2B
mutations in 93 patients, with congenital central hypo-
ventilation syndrome (CCHS) from within and outside
Europe. A wide variety of mutations were identified. While
the most frequently reported mutation was a variable
expansion of a 20-alanine stretch ranging from +5 to +13
alanines within exon 3 of the PHOX2B gene, frameshift
and missense mutations also occur but only occasionally
within exon 1, 2 or 3 of the PHOX2B gene [30,31,39,40].
The presence of a PHOX2B mutation confirms the diag-
nosis of CCHS.
Molecular diagnosis of PHOX2B mutations in CCHS
patients is performed by PCR amplification and sequen-
cing analysis initially in exon 3 of PHOX2B gene [39]. If
no mutations are detected, sequencing analysis is under-
taken in PHOX2B exon 1 and exon 2. Parents of a child
with a mutation can request analysis of their own DNA.
When a polyalanine expansion is detected, a more specific
analysis is performed to identify whether the mutation is a
constitutive mutation, which is carried by all cells of theindividual, or a mosaic mutation, carried only by a fraction
of cells in which the mutation has been acquired after
fertilization. In particular, mosaicism is caused when a
mutation arises within an individual cell during em-
bryogenesis. Only tissues that derive from that cell will
harbour the mutation in the individual. The resulting
individual will have a mixture of cells, some with, and
some without the mutation. Mosaicism can be germline
(affecting egg or sperm cells) or somatic (affecting non-
germinal cells). CCHS patients with polyalanine expansions
may have a somatic or germline mutation. In a germline
mutation, CCHS is transmitted to the offspring if they in-
herit the PHOX2B allele carrying the mutation as CCHS is
autosomal dominant disorder. However, if the individual
inherits the wild-type allele, the child will be a healthy
individual.
To identify the mosaic transmission of the allele, a sensi-
tive diagnostic method is used which couples amplification
of the shorter amplimer spanning only the polyalanine re-
gion, with FAM-tagged primers, and capillary electrophor-
esis. Polyalanine expansion mutations produce two peaks
on electrophoresis which represent the expanded polyala-
nine and the wild-type alleles.
The ratio of the area under the expanded allele (E) and
the sum of the area under both wild-type and expanded al-
leles (E +N) is a measure of polyalanine expansion length.
The ratio (E/E +N) decreases with increasing length of the
polyalanine expansion. Analysis of PHOX2B mutation in
parents who are carriers of CCHS show that mosaic
carriers have smaller E/E + N ratios (with polyalanine
expansions >5 alanine residues), while constitutive carriers
have ratios consistent with a +5 alanine expansion.
The constitutive +5 alanine expansion may be completely
or partially penetrant, and may lead to CCHS, late-onset
CCHS, or an asymptomatic individual. However, consti-
tutive expansions ≥ +6-alanine expansion are completely
penetrant. A consequence of this observation is that asymp-
tomatic CCHS parents of a proband carrying the +5-
alanine expansion may have a constitutive mutation,
while the asymptomatic parents of a proband with ex-
pansions longer than +5-alanine expansion have a mosaic
mutation. Therefore, +5 alanine expansions are constitu-
tive mutations associated with incomplete penetrance in
parents, while >5 alanine expansions are mosaic mutations
in asymptomatic parents but may be constitutive muta-
tions in symptomatic carriers.
In our cohort of patients and parents most of the poly-
alanine expansions are de novo mutations with only a
small fraction of patients inheriting the illness from a
parent with a constitutive or mosaic mutation [31]. Until
recently it was thought that about 10% of PHOX2B poly-
alanine expansions were inherited from one parent. How-
ever, recurrence risk of CCHS depends on the origin of
the PHOX2B mutation. In the case of de novo mutations
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cause the mutations are very rare. In the case of inher-
ited mutations, if derived from a constitutive carrier,
the risk of transmission is 50%, while when derived
from a mosaic carrier the risk of transmission is less
than 50%.
The detection of low levels of PHOX2B mosaicism
using both short and long amplimers in the ‘FAM’ and
‘sequencing’ method have been compared [40]. Sequencing
was not very efficient in detecting low levels of mosaicism,
with both the long, and the short amplimer. The short
amplimer detected 30 to 50% and the long amplimer 50%
or more mosaicism depending on the length of the polyala-
nine tract. In contrast, the ‘FAM’ method was much more
sensitive: the short amplimer was able to detect all levels of
mosaicism for each polyalanine expansions, and the long
amplimer was able to detect from 2 to 10% mosaicism
which correlated with the respective length of the polyala-
nine expansion. The short amplimer was more efficient
in detecting PHOX2B expansion, and the ‘FAM’ method
more sensitive than ‘sequencing’ method. The best com-
bination for analysing PHOX2B polyalanine expansion
levels is therefore to use the shorter amplimer, followed
by FAM labelling. Applying this technique to patients’
parents, previously resulted not to carry the proband’s
mutation by using the ‘sequencing’ method, increased
the transmission of inherited PHOX2B mutations from
10% to 25%. In conclusion our data show that, compared
to the sequencing method, the ‘FAM’ method is able to
detect a lower percentage of mosaicism in CCHS parents
carrying polyalanine expansions.
These observations suggest that all CCHS parents, who
have been previously analysed by the sequencing method
should be re-evaluated using the FAM method to exclude
low levels of mosaicism and to better predict the risk of
CCHS transmission to the proband. Values of the ratio
(E/E + N) obtained by serial dilutions of DNA carrying
different length polyalanine expansions provide an esti-
mate of the extent of mosaicism.
The detection of somatic mosaicism in the parent of a
child with CCHS is confirmation of the presence of a
germline mutation. The risk of parents transmitting a
somatic mosaicism is 50% or lower, but it is difficult to
estimate because the extent of mosaicism in somatic
cells may be different from mosaicism in germline cells.
A polyalanine somatic mosaicism in parents may also
have implications, if there is incomplete penetrance or
late-onset CCHS.
Levels of the mosaicism detected by the FAM
method are not definitive because the limit of detec-
tion may be improved by new technologies. Some
negative parents identified so far by the FAM method
could carry a low level of the mutant allele, which is
still unidentified.Hints on potential future treatments from other
homopolymer associated diseases
Kenneth H. FISCHBECK. Neurogenetics Branch, Na-
tional Institute of Neurological Disorders and Stroke,
National Institutes of Health, Bethesda, Missouri, USA
Polyglutamine (polyQ) disorders, such as Huntington’s
and Kennedy’s disease [41], and polyalanine disorders,
including CCHS [42], are all single amino acid repeat ex-
pansion conditions. They may therefore share some im-
portant underlying pathological mechanisms that lead to
neuronal loss. The lessons learned from research into
polyQ disorders, including the challenges of developing
effective treatments in humans, may well be applicable
to CCHS.
Huntington’s disease (HD) is one of at least nine differ-
ent polyQ neurodegenerative disorders. It results from an
autosomal dominant mutation which causes abnormal in-
voluntary writhing movements called chorea. It usually
presents in patients over the age of 30 years. The symp-
toms include psychological changes, depression, impulsive
behaviour and cognitive decline. There is widespread loss
of neurons in the central nervous system, particularly in
the cerebral cortex and basal ganglia. Most vulnerable are
the striatal medium spiny neurons in the caudate nucleus.
The mutation is a CAG trinucleotide repeat expansion of
40–60 or more CAGs compared with an average of 20
CAGs in normal individuals. The product of the mutant
HD gene is called huntingtin, and its function is unknown
[41,43]. Cell culture and animal studies indicate that it
may play a role in vesicular transport or in the regulation
of transcription [44].
Kennedy’s disease is an adult-onset, X-linked motor
neuropathy, also known as spinal and bulbar muscular
atrophy. It leads to weakness of the face, tongue and the
pharyngeal muscles, as well as the extremities. Respiratory
muscles may also be affected and, like CCHS patients,
those with Kennedy’s disease may develop CO2 retention
and respiratory failure. Only men are fully affected by
this disease; female relatives are generally asymptomatic
[45,46]. In contrast to Huntington’s disease, the normal
function of the gene product, the androgen receptor
protein, is well known.
Kennedy’s disease is caused by an expansion of a CAG
repeat in the first exon of the androgen receptor gene.
CAG repeats in the mutant AR gene range from 40 to
62 CAGs, whereas normal individuals have 10 to 36 CAGs
[41,43]. There is a correlation of repeat length with disease
severity; the longer the repeat, the earlier the onset and
the more severe the disease [47].
The androgen receptor (AR) is a nuclear hormone re-
ceptor, and in the absence of ligand it is found in the
cytoplasm. It has a transactivation domain with a polyglu-
tamine tract, and DNA and ligand binding domains. When
a hormone ligand (testosterone or dihydrotestosterone)
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formational change, dissociates from heat shock proteins,
and partners with another AR receptor to form a dimer.
The AR dimer binds to a specific sequence of DNA and
interacts with other proteins in the nucleus to up- or
down-regulate specific targets [48].
Ligand binding is unaltered by the repeat expansion [49].
As with PHOX2B in CCHS, there is abnormal target gene
activation by the mutant AR protein. There is some loss of
AR function in patients with Kennedy disease, as mani-
fested by signs of androgen insensitivity [50]. However,
studies show that loss of AR function alone, as in androgen
insensitivity syndrome [51] does not cause the motor
neuron degeneration that occurs in Kennedy disease.
The primary effect of the repeat expansion is a toxic
gain-of-function in the mutant AR protein. The protein
misfolds and has the tendency to form aggregates. These
aggregates (or at least the tendency of the mutant protein
to aggregate) may be toxic to the motor neurons in the
brainstem and in the spinal cord, causing progressive motor
neuron degeneration. This toxic gain-of-function has been
demonstrated in experimental models and is the likely
mechanism for neurodegeneration which leads to selective
neuronal loss in this and other polyQ disorders [52].
The toxicity of the AR protein is related to the length
of the expanded polyQ tract and is greater in the nu-
cleus than in the cytoplasm [53]. The mutant AR protein
binds to other proteins in the nucleus, depleting critical
nuclear factors, which may lead to transcriptional dys-
regulation with altered histone acetylation [54].
Neurons are protected from the effects of the AR mutant
protein by the ubiquitin–proteasome pathway and by heat
shock proteins, which serve as molecular chaperones.
Misfolded proteins and their aggregates are targeted for
degradation by the ubiquitin–proteasome pathway, while
chaperone proteins assist in refolding, dissembling, and
reassembling proteins. Neuronal inclusions of mutant pro-
tein in mouse models and human tissue stain positively
for components of the ubiquitin–proteasome pathway
[55-58]. This pathway degrades truncated fragments of the
androgen receptor, and molecular chaperones such as
HSP90 may target the mutant proteins for degradation
[59]. Inclusions of mutant proteins are observed not only
in the nucleus but also in the cytoplasm of cultured neur-
onal cells [60] in transgenic animal models [61] and in
autopsy material [62]. It is now thought that inclusions of
mutant proteins may reflect a protective response by the
cell to the toxic protein.
As the mutant AR protein is toxic in the presence of
androgen, drug treatments that reduce androgen levels,
such as leuporelin and dutasteride, have been investigated
in humans following promising results in animal models.
In humans, leuprorelin only had a significant effect on
swallowing in a post hoc analysis of patients who had beensymptomatic for less than 10 years [63]. While quality of
life improvements were observed with dutasteride, there
were no significant effects on muscle strength [64].
There are on-going research programs investigating AR
modulation in animal models, the effect of geldanamycin
derivatives on the protective response of heat shock pro-
teins, the efficacy of curcumin derivative ARCJ9, and the
effectiveness of insulin-like growth factor-1 (ICG-1) on
neuroprotection and muscle regeneration.
PolyQ disorders, unlike CCHS, are late-onset, progress
very slowly, and a large patient sample or a long follow-up
period is required to test the efficacy of treatments on dis-
ease progression. Both mouse models and clinical studies
suggest that for treatments to be effective, they must be
started early in the course of the disease. To achieve this,
widely available genetic tests, relevant therapy targets, and
reliable clinical outcome measures are required, as well as
biomakers to assess the likely effectiveness of treatment.
Potential new therapeutic targets for investigation include
agents that block gene expression and intercellular trans-
port of mutant proteins, especially those that enhance the
protective mechanisms that degrade the mutant protein
and those that mitigate the toxic effects of mutant protein
by correcting transcription and signal transduction defects.
Cell culture models offer assay systems for screening
chemical compound libraries, with medicinal chemistry
to optimize the hits. Biological approaches including oli-
gonucleotides that reduce RNA transcripts of the mutant
gene are under development for these and other neuro-
degenerative diseases.
In conclusion, to develop effective treatments for these
diseases researchers need to address the following: (i) Is it a
loss-of-function or a toxic gain-of-function mechanism; (ii)
Is it a gene that needs to be replaced or one that needs to
be knocked down; (iii) Is it a developmental disorder that
can only be treated before birth or in early infancy, or is it a
condition with an on-going toxic effect of a mutant protein,
or the effect of a deficiency in the mutant protein that
might be amenable to treatment later in life, after diagnosis.
Important needs include a network of clinicians and
patients for clinical studies, clinical protocols with relevant
outcome measures and family groups available for study,
and early involvement of pharmaceutical companies to
make use of their expertise and knowledge in developing
effective treatment.
Desogestrel: facts and hope
Ha TRANG, Thomas SIMILOWSKI, Christian STRAUS.
French Centre of Reference for Central Hypoventilation,
Robert Debre University Hospital and La Pitié Salpêtrière
University Hospital, Paris, France
The observations that the response to CO2 was restored
in two female patients with CCHS taking desogestrel as a
contraceptive pill has led to hypothesis that progesterone
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a result, a clinical study to evaluate the effect of the drug on
the respiratory response to CO2 in CCHS patients is cur-
rently in progressb. We review here the cases of the two
female patients with neonatal CCHS, who at puberty re-
ceived desogestrel as a contraceptive pill and hypothesize
on the mode of action of desogestrel in restoring ventilatory
response to CO2.
Both female patients were diagnosed with CCHS at
birth and followed-up since then in the French Centre of
Reference of Central Hypoventilation. The first patient
was 19 years old at the time she was taking desogestrel.
She had a +5 alanine expansion on the PHOX2b gene.
Since birth she had hypoventilated and required mechanical
ventilation during the night. In 2006, she had no respiratory
response to the exogenous CO2 challenge test. Three years
later, when the test was repeated, there was a dramatic in-
crease in respiratory rate and volume. On taking her med-
ical history, it was revealed that she been taking desogestrel,
as a contraceptive treatment for one year. The second pa-
tient was 30 years old at the time it was observed that her
ventilatory control had improved. Like the previous patient
she required mechanical ventilation during the night. She
had a +6 alanine mutation in the PHOX2B gene. In July
2009, she had not responded to the CO2 challenge test. At
this time she asked for a contraceptive and, in December
2009, received desogestrel. Three weeks later, a CO2 chal-
lenge test was performed which revealed a marked increase
in respiratory and ventilation rates in response to increase
of inspired CO2. Both patients showed a marked recovery
in response to CO2; the only feature they shared was treat-
ment with desogestrel.
Following these observations, a literature research re-
vealed only one report in which a pregnant CCHS patient
was studied. During pregnancy which is physiologically as-
sociated with an explosion in progesterone and estrogens
secretion, there was no change in her chemosensitivity to
CO2, oxygen or response to hypoxia. In the author’s co-
hort, those CCHS patients using contraceptives, other
than desogestrel, do not show evidence that these drugs
affect chemosensitivity to CO2.
From these observations, it is hypothesised that desoges-
trel is a potent progesterone receptor agonist that induces
changes in respiratory control by activating autonomic CO2
chemosensitive regions that are unaffected by PHOX2B
mutations, such as chemoreceptors in the hypothalamus
and the peripheral nervous system. There is evidence that
progesterone can enhance ventilatory response to hyper-
capnia, and animal studies which indicate that progesterone
acts in the brain.
Keynotes on basic sessions
Isabella CECCHERINI, PhD. Laboratorio di Genetica
Molecolare, Istituto Giannina Gaslini, Genova, ItalyThis summary is dedicated to those with CCHS and to
their families. It outlines our basic understanding of the
condition which has allowed us to raise patient’s expect-
ation of care and helped to impact the quality of their
lives. The advancement in our knowledge of CCHS is
reviewed, in simple terms, starting with the underlying
genetic and pathological origins of the illness, and fi-
nally addresses the developments in pharmacological
treatments for CCHS.
For many years, CCHS was considered a lethal genetic
disorder, until medical advancements allowed patients to
have their own families. CCHS is a disease which recurs
in families, with a 50% risk of transmission from affected
parents to their offspring. The birth of a CCHS patient
from families without any history of the disease cannot
be avoided or prevented. Mutational events occur randomly
and rarely, at each gene locus and at each cell division. The
chance that the PHOX2B gene is affected by a new muta-
tion is very low, but not negligible. Therefore, the birth of a
child with CCHS in families without any history of the
disease will occur. If new mutational events cannot be
prevented and their occurrence cannot be avoided, re-
cent methodological approaches can help predict the
risk of recurrence, once PHOX2B mutations and som-
atic mosaicism are identified in patients. De novo muta-
tional events cannot be avoided. In such families, when
a child is born with CCHS, genetic counseling can help
both parents and their children, cope with the condi-
tion and understand the risk of transmitting CCHS to
any future children.
In vivo and in vitro studies have deepened our under-
standing of the pathogenic mechanisms involved in CCHS.
They have identified the neuroanatomic lesions underlying
the impaired perinatal hypercapnic response, and charac-
terised the aggregates of misfolded PHOX2B proteins and
their effect on cellular response. PHOX2B proteins also
interact with other proteins regulating gene expression and
cell signaling, thus accounting, once defective, for not
only the respiratory phenotype, but also the development
of accompanying disorders such as neuroblastoma and
Hirschsprung disease. These are a few of the advances that
have been made.
And finally, the increase in ventilatory responses to
hypercapnia observed in two patients using desoges-
trel raises hope for a pharmacological approach in
CCHS. Further clinical research studies should be
undertaken to that purpose. Pharmacological therapies
developed for polyglutamine disorders may be effect-
ive in CCHS. In vitro screening of specific drugs has
already demonstrated a reversal of mutation-impaired
PHOX2B function. I would like to thank all the speakers
who have contributed to this interesting session today,
and also to all the families who passionately followed our
discussions.
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Debra E. WEESE-MAYER, M.D. Autonomic Medicine
in Pediatrics (CAMP), Ann & Robert H. Lurie Children’s
Hospital of Chicago. Northwestern University Feinberg
School of Medicine, Chicago, Illinois
Respiratory and Autonomic Disorders of Infancy, Child-
hood and Adulthood (RADICA) are a group of rare
diseases that have varying presentation, combined with
a range of severity of respiratory control and auto-
nomic nervous system dysfunction. Among these con-
ditions, CCHS and Rapid-onset Obesity with Hypothalamic
dysfunction, Hypoventilation, and Autonomic Dysregulation
(ROHHAD), have the most severe respiratory phenotypes
and require life-long support with artificial ventilation as a
mainstay of care. The cause of ROHHAD is not known at
the present time. But studying a condition with a related
phenotype, such as CCHS, may enable a better understand-
ing of ROHHAD and the control of breathing within the
autonomic nervous system dysregulation. This presentation
briefly reviews the phenotypes of these two disorders.
In 1970, the first case of CCHS was reported by Robert
Mellins and colleagues. More than 30 years later, in 2003,
PHOX2B was identified as the disease-defining gene for
CCHS. Approximately, 90% of CCHS patients are heterozy-
gous for polyalanine repeat expansion mutations (PARMS)
in the second polyalanine repeat region of the PHOX2B
gene. These expansions have between 24 and 33 alanines in
exon 3 of the PHOX2B gene on the affected allele (and
20 alanines on the unaffected allele). So CCHS-related
PHOX2B genotypes are 20/24 to 20/33. The remaining
10% of CCHS patients have a non-polyalanine repeat
expansion mutation (NPARM) in exon 2 or exon3.
NPARMs are usually missense, nonsense or frameshift
mutations.
Since 2010, with publication of the 2nd American
Thoracic Society (ATS) Statement on CCHS, a PHOX2B
mutation is required to confirm a diagnosis of CCHS.
Over 1,000 PHOX2B mutation-confirmed cases of CCHS
have been reported worldwide and the most common ge-
notypes are 20/25, 20/26 and 20/27 PARMs. In addition to
abnormal respiratory control, CCHS is also associated
with a predisposition to Hirschsprung disease, neural crest
tumours, cardiac rhythm dysfunction, characteristic facial
features, ophthalmologic abnormalities, and more in terms
of autonomic dysregulation.
The severity of hypoventilation, autonomic symptoms,
and predisposition to neural crest tumours increases with
the length of the polyalanine repeat expansion. Individuals
with 20/26 to 20/33 PARMs and those with NPARMs
have a higher risk of Hirschsprung disease. Patients
with PARMs 20/29-20/33 and, especially those with an
NPARM, have a predisposition to tumours of neural crest
origin. Neuroblastoma occurs primarily in NPARMs, while
ganglioneuroma, ganglioneuroblastoma and occasionallyneuroblastoma develop in a small subset of those with the
longest PARMs.
Children with CCHS have cardiovascular, respiratory
and ophthalmologic symptoms consistent with autonomic
nervous system dysfunction. Holter monitoring in CCHS
subjects shows a positive correlation between the num-
ber of alanine repeats and longest r-r interval duration
(≥3 secs). Patients with a 20/27 genotype are at greatest
risk of cardiac pauses (83%), and more likely to receive
a cardiac pacemaker than those with the 20/25 or 20/26
genotypes (0% and 19%, respectively). Failure to receive a
pacemaker when the r-r interval is ≥3 secs may lead to
death or severe neurocognitive defects.
Respiratory control is impaired in CCHS, and individuals
with NPARMs typically have a more severe continuous
ventilator dependence than those with PARMS. During
sleep, ventilatory sensitivity to endogenous hypercapnia,
hypoxia or the combined stimulus is negligible or absent.
So individuals with CCHS will not increase their breathing
in response to these physiologic stimuli, nor will they
spontaneously arouse from sleep. With awake exogenous
challenges of combined hypercapnia-hypoxia, virtually
all patients with CCHS, irrespective of genotype, have a
delayed response with a modest but insufficient increase in
minute ventilation. This residual responsiveness to a
hypercapnia-hypoxia challenge suggests that pharmacologic
interventions may be effective in recovering chemosensory
function and the perception of asphyxia.
Pupillometry studies with a handheld pupillometer
have demonstrated impairment in both sympathetic and
parasympathetic nerve function in CCHS patients when
compared with normal control subjects. There is an inverse
linear relationship in the diameter, constriction and dilation
velocities of a patient’s pupillary response to light and
length of the most common PHOX2B PARM genotypes.
This suggests a graded CCHS phenotype/PHOX2B geno-
type response based on polyalanine repeat length, which
may provide an objective outcome measure in interven-
tion trials.
Patients with CCHS have characteristic facial features
that differ from matched control subjects. Facial photo-
grammetry of midface and lip (lip trait is the overturned
lateral one-third of the upper vermilion border, so flesh-
colored instead of pink) trait variables correctly predicted
85.7% of CCHS cases and 82.2% of control subjects. Sever-
ity of these facial features, including flattening of the face
and shortening of the upper and midface, increase with
the length of the PHOX2B alanine repeat expansion.
At present there is no correlation between neurocogni-
tive ability of school-age children with CCHS and specific
PHOX2B genotypes.
Later-onset CCHS (LO-CCHS; individuals ≥ one month
of age) typically have the PHOX2B 20/24 and 20/25 geno-
types, and may not be identified until well into adulthood.
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normal responses to carbon dioxide and oxygen chal-
lenges. Hirschsprung disease and tumours of neural crest
origin are rare. Cardiac asystoles can occur in adults with
LO-CCHS, but thus far have not been reported in chil-
dren. Neurocognitive function may be impaired in those
not identified until adulthood, but specific testing of
children with LO-CCHS has not been reported. While
children with LO-CCHS have the characteristic CCHS-
related facial features, the facies are more difficult to
identify in adults especially if they have a moustache that
disguises the “lip trait”.
Patients with de novo deletions of the PHOX2B gene
present with variable phenotypes, including total gut agan-
glionosis, ganglioneuroblastoma, swallowing difficulties and
apparent life-threatening events. These children generally
lack significant portions of the PHOX2B gene and sev-
eral other nearby genes. The condition has an auto-
somal dominant inheritance pattern but may occur de
novo. The expectation with the heterozygous condition
and absent PHOX2B gene, would have been one of
haploinsufficiency.
In contrast to CCHS, the onset of ROHHAD occurs
after 1.5 years of age in otherwise seemingly healthy chil-
dren. Early recognition and treatment of the symptoms
associated with ROHHAD are essential as there is a high
prevalence of cardio-respiratory arrest. At present, there
is no diagnostic test, and no defining gene has been identi-
fied. The disease is not widely recognized by healthcare
professionals, though with recent efforts nearly 100 cases
have been reported. Forty percent of these cases present
with ganglioneuroma or ganglioneuroblastoma.
The ROHHAD phenotype evolves with advancing age
and is characterized by rapid-onset obesity in the first
7–10 years of life, followed by hypothalamic dysfunction,
onset of symptoms of autonomic dysregulation and later
onset of alveolar hypoventilation. Obesity is accompanied
by growth deceleration, and weight loss does not lead to
reduced hypoventilation. Children with ROHHAD typic-
ally have an absent or attenuated response to hypoxia and
hypercapnia, though not formally reported. There is a
wide variation in the interval between the onset of hypo-
thalamic dysfunction, autonomic dysregulation and hypo-
ventilation, and the severity of the phenotype evolves with
advancing age.
Ophthalmologic defects manifest as increased dilation
(mydriasis) and decreased contraction (myosis) of the pupil
to light stimuli when compared with control subjects,
suggesting sympathetic and parasympathetic neuronal
dysfunction. Thermal regulation is also impaired in
ROHHAD patients which manifests as peripheral ex-
tremity hyperthermia at night and peripheral extremity
hypothermia during the day, indicating altered vasomotor
tone and temperature dysregulation.ROHHAD patients may have changes in behaviour
and mood, and the subset that has experienced a cardio-
respiratory arrest may have significant neuro-developmental
impairment. In a subset of individuals with ROHHAD,
the Intelligence Quotient (IQ) score is reduced, likely
reflecting those who experienced an arrest or those whose
hypoventilation went unnoticed and without adequate
ventilatory support. However, a remarkably high percentage
of children with ROHHAD have normal or high IQs (above
120). At present, treatment for ROHHAD is symptom-
based as for CCHS. The primary goal is to optimize the
neurocognitive potential of these children. Care requires
the services of a multidisciplinary team, parental support
and greater awareness of the condition among all health-
care professionals—especially the general paediatrician who
will identify the rapid weight gain on the plotted growth
curve at a well-child visit.
Both CCHS and ROHHAD are diseases of the autonomic
system and have severe respiratory phenotypes. However,
PHOX2B mutations are not present in patients with ROH-
HAD. This finding indicates that a different genetic path-
way is involved in the differentiation or development of the
ROHHAD phenotype.
Sharing information on CCHS, ROHHAD and other
disease of RADICA may help us to understand the control
of breathing within the autonomic nervous system and
the genetic pathways that lead to the development of these
conditions, in addition to understanding the basic under-
pinnings of respiratory control and autonomic regulation
in healthy children.What’s new in ventilatory support?
Matthias FRERICK, MD. Klinikum Dritter Orden, Munich,
Germany
Hypoventilation is the hallmark of CCHS and therefore
life-long artificial ventilation delivered either by positive
or negative pressure ventilation is needed [65]. Positive
pressure ventilation may be delivered by invasive or non-
invasive means; while negative pressure ventilation is
mostly provided by breathing pacemakers. This article
briefly reviews the outcomes of long term home mech-
anical ventilation (HMV), the performance of ventila-
tory devices and the socio-medical aspects of long-
term ventilation.
Studies about HMV have investigated the clinical set-
ting for the initiation of HMV and the reasons for re-
admission to hospital after extended use of the ventila-
tors. A study comparing 28 patients with nocturnal
hypoventilation randomised to receive either initiation
of HMV as outpatients, or as inpatients found that there
was no difference between the two groups for blood gas
tensions, ventilator compliance, healthcare professional
contact time, and time in hospital. Outpatient initiation
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procedures [66].
After initiation of HMV via tracheostomy in 109 paediat-
ric patients with chronic respiratory failure, 44/109 (40%)
patients were re-admitted to hospital within 12 months.
Fifty percent of admissions occurred during the first
three months after index discharge. The reasons for re-
admission included cannula related problems, infections of
the airways and lung. Only a change in the child's treatment
before discharge was associated with re-admissions shortly
after index discharge, indicating that stability of the condi-
tion before discharge is highly important. In order to man-
age HMV users’ expectations, it is important that all those
who use or administer HMV support, carers, patients, and
parents, are aware of the possibility of re-admission to
hospital [67]. An assessment of the remoteness of the
health centre (100 km) from HMV-dependent children
and their family as well as their level of education do not
appear to affect mortality rate and patient outcomes [68].
Prolonged positive pressure ventilation carries potential
complications, including diaphragm atrophy. This has been
observed in both animal and human studies. Levine et al.
[69] compared diaphragm biopsies of 14 brain dead organ
donors with intraoperative diaphragm specimens from 8
control subjects undergoing operations for chest problems.
Diaphragmatic inactivity and mechanical ventilation was
sustained for 18 to 69 hours in the case subjects and for 2
to 3 hours in control subjects. After only 18 hours of posi-
tive pressure ventilation the diaphragm of case subjects
showed marked atrophy. Compared to control biopsy dia-
phragms, the specimens from case subjects showed a 57%
decrease in the area of slow twitch fibres and a 53% de-
crease in fast twitch fibres. Diaphragm muscle atrophied
faster than skeletal muscle. Inactivity of the diaphragm led
to oxidative stress and increased proteolysis resulting to
muscle atrophy, and was not due to inflammation.
Bench tests are used to assess the performance of non-
invasive home mechanical positive-pressure ventilators
(NI-HMPPV) using settings representative of common
respiratory insufficiencies. In a study of 17 non-invasive
positive-pressure ventilators in which assisted control,
pressure support ventilation or both, if available, were
tested, no single ventilator was able to adequately venti-
late six common paediatric ventilatory patterns. Only few
ventilators were able to ventilate the youngest patients.
The sensitivity of the flow and pressure triggers were in-
sufficient, although the pressure trigger was better with a
closed circuit, and the flow trigger worked better with
open systems [70]. Physicians should be aware of ventila-
tor performance when selecting a HMV for patients.
A lung bench test study assessing the maintenance of
minimal tidal volume by NI-HMPPV has compared the
performance of 6 ventilators during baseline alveolar
hypoventilation, and hypoventilation associated with anincrease in airway resistance, a decrease in lung com-
pliance, and non-intentional leaks. The six ventilators
maintained a minimal tidal volume during an increase
in airway resistance and a decrease in lung compliance.
The maintenance of a minimal tidal volume during a
non-intentional leak was associated with large variations
in tidal volume and patient-ventilator dyssynchrony. Some
devices showed an overshoot of the tidal volume after the
leak was closed, which may lead to fragmentation of
the sleep, or poor ventilator tolerance. This outcome is
also reported in other studies including ventilators using
double circuits [71].
Volume-assured non-invasive positive pressure ventila-
tion is a novel mode in which circuit leaks have little effect
on the delivered respiratory minute ventilation. However,
these ventilators are not currently available for HMV [72].
In a study of the user friendliness of HMVs, physicians in
ICU, without practical experience of HMVs, were assessed
on their ability to operate 11 HMVs. Compared to trained
technicians, physicians were slower to operate the ventila-
tors and made mistakes, suggesting the need to standardise
the ergonomics of these machines, and to train ICU physi-
cians to use them [73].
Computer control of mechanical ventilators using arti-
ficial neural networks (ANNs) may increase the safety of
mechanical ventilation. In principle ANNs offers signifi-
cant advantages over the rule-based system used by HCPs,
as ANNs have the potential to learn and adapt to the indi-
vidual patient's response. An initial study has compared
settings chosen for 10 virtual patients by 10 clinical
experts. Not only did the expert’s choice of setting all
concur; 10 of the 40 ANNs were also able to control
the ventilator. In the future, ANNs may have a role in
optimising ventilator settings and helping physicians
resolve ventilator anomalies [74].
In contrast to positive-pressure ventilation, negative
pressure ventilation delivers air in a physiological way
to the lungs and has been shown in surfactant depleted
rabbits to provide better oxygenation and cause less
lung injury [75].
Negative pressure ventilation by phrenic nerve pacing
allows patients freedom from the mechanical ventilator
during the day [76,77]. The common complications of
phrenic pacing include re-operation due to damage of im-
planted components [78], although these are decreasing
due to improvements in device components; receiver
pocket infection; axonal damage of the phrenic nerve
has been reported in one patient after 13 years of pacing.
Phrenic pacing in patients with spinal injuries leads to
improvements in quality of life [79-81]. Compared to
mechanical ventilation, phrenic nerve stimulation leads
to significant reduction in respiratory tract infections
[80]. New devices for direct diaphragm pacing are cur-
rently under evaluation.
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HMV provision throughout Europe [82]. To investigate
this, Dybwik et al. [83] undertook focus group studies,
on HMV treatment, with a wide range of HCPs, which
included nurses, pulmonologists and paediatricians across
Europe [83]. The most important factor in determining
HMV provision was the enthusiasm of skilled HCPs. Atti-
tudes of HCPs, rather than resources, appear to be the
pivotal driving force for access to HMV.
Medical problems are also social problems and affect
children, parents and caregivers in different ways. Par-
ents and caregivers find living with HMV-dependent
children stressful and feel that their child’s life is not val-
ued by society. Experiencing this pressure and problems
parents felt it made them a better and stronger person. In
contrast, HMV children view the ventilator and hospitals
as normal part of their lives, friendships were more im-
portant than their medical problems [84]. Nevertheless
children hide aspects of their illness from the outside
world to avoid isolation and rejection by their friends
and society.
Sociological frameworks such as Goffman's theory of
’Stigma‘ may help HCPs to understand the social problems
encountered by HMV-dependent children [85]. These
children are often discriminated against, unvalued, dis-
credited and isolated. HCPs should support and foster a
socialization processes that eliminates stigmatizing lan-
guage and stereotypes.
In conclusion, all HMV modalities are still ‘state of the
art’ and provide the best available support for CCHS pa-
tients. Prior to discharge and HMV, patients need to be
medically stable. Bench tests show the strengths and weak-
nesses of ventilators and users of ventilators must know
their limitations. New technology may help to optimise
ventilator settings. Direct diaphragm pacing is new, and
may be an option in CCHS. HCPs need to address both
medical and social problems of their patients to enable
them to have a better quality of life.
Criteria for cardiac pacing in children and the general
population
Katarzyna BIEGANOWSKA, MD. Department of Car-
diology, Children’s Memorial Health Institute, Warsaw,
Poland
In 1958, the first cardiac pacemaker was implanted into
a middle aged man. Nearly four years later the first pace-
maker was implanted into a seven year old boy post oper-
ation of tetralogy of Fallot because of syncopes associated
with bradycardia. Bradycardia (bradyarrythmia) may cause
chronic or intermittent low cardiac output, and patients
may present pre-syncopal or syncopal attacks, exercise
intolerance and progressive heart failure. In general, the
incidence of pathological bradycardia rises with age of
the patient.Bradyarrythmia is the main indication for permanent
cardiac pacing and may present as atrioventricular heart
block or sinus node dysfunction.
Atrioventricular block may be congenital or acquired
mainly post congenital heart diseases operations. In this
condition, the sinus node works normally but ventricular
rate is dependent on the escape rhythm, which is much
slower, atrio-ventricular dissociation is present (no correl-
ation between the sinus and escape rhythms).
Sinus node dysfunction (also known as sick sinus
syndrome - SSS) describes a range of heart rhythm
disorders, which include bradycardia (sinus bradycardia,
sinoatrial block, sinus arrest), tachycardia and bradycardia-
tachycardia. SSS occurs rarely in infants and children and
is usually due to congenital heart abnormalities. Risk
factors for SSS include symptomatic bradycardia, fre-
quent sinus pauses, pre-syncope, syncope, heart failure,
symptomatic chronotropic incompetence, inadequate
heart rate response to physical activity and symptom-
atic sinus bradycardia resulting from drug therapy.
In some patients, incidences of bradycardia and symp-
toms are transient and may be detected only by long-term
ECG monitoring. Commonly used noninvasive methods
such as ambulatory 24-48-hour Holter ECG recording,
transtelephonic ECG or event Holter allow for correlating
symptoms with heart rhythm only if the symptom of
interest occurs during monitoring. The PocketECG a new
technological solution allowing for continuous, noninva-
sive, real-time ECG monitoring, became available recently.
The implantable Loop Recorder ECG (ILR) is an invasive
method for registering heart rhythms and is particularly
useful when symptoms are infrequent or when aggregate
long-term data is required.
In general, the indications for pacemaker implantation
are similar in children, adolescents and adults. In 2008,
the American College of Cardiology, the American Heart
Association, and the Heart Rhythm Society jointly pub-
lished guidelines for device-based therapy of cardiac
rhythm abnormalities [86]. They divided the indications
for pacemaker implantation into three specific categories,
Class I, (disturbances requiring permanent cardiac pacing,
provided the dysfunction was not transient), Class II
(permanent pacing is reasonable to performed) and
Class III (permanent pacing should not be performed).
This year the European Society of Cardiology’s (ESC)
new guidelines on cardiac pacing and cardiac resynchroni-
zation therapy were published, the main indications are
similar to those of previous guidelines.
Class I
Permanent cardiac pacing is indicated in children for
advanced second- or third-degree atrioventricular block
associated with symptomatic bradycardia – pre-syncope,
syncope, ventricular dysfunction or low cardiac output, in
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tricular block lasting longer than 7 days after cardiac
operation.
A pacemaker implantation should be performed in chil-
dren with congenital atrioventricular block and with one
of the risk conditions: a wide QRS escape rhythm, or com-
plex ventricular ectopy, or prolonged QTc interval, or
ventricular dysfunction or with very slow ventricular rate
(<50/beats per minute or pauses >3 times the basic cycle
length). Permanent cardiac pacing is indicated in children
with SSS and correlation of symptoms during bradycardia.
Cardiac pacemaker implantation is also indicated for ad-
vanced second-degree or complete AV block associated
with neuromuscular diseases, for second-degree AV block
with symptoms, for asymptomatic patients with average
ventricular rate of ≤40 bpm or faster if cardiomegaly or
LV dysfunction is present or if the site of block is below
the AV node (wide QRS complexes). The procedure is also
necessary in adults with SSS and symptoms attributed to
bradycardia (for example atrial fibrillation and bradycardia
with one or more pauses of ≥5 seconds) and in those with
acquired atrioventricular block (irrespective of symptoms
for example after catheter ablation of the atrioventricular
junction).
Class II
Permanent cardiac pacing is reasonable in children with
congenital heart disease and sinus bradycardia for the pre-
vention of recurrent episodes of bradycardia mediated
tachyarrhythmias or with a resting heart rate <40 bpm and
cardiac pauses >3 seconds. In children post cardiac sur-
gery with bifascicular block complicated transient compete
heart block.
In patients with long QT syndrome, bradycardia and
symptoms in spite of B-blockade, left stellate ganglio-
nectomy or implantable cardioverter-defibrillator should
be considered rather than pacemaker implantation.
The children with neurocardiogenic pre syncope and
syncope as a result of transient autonomic nervous system
dysfunction, which is likely resolve by the age of 18 years
usually don’t need permanent cardiac pacing therapy.
Patients with CCHS who present with life-threatening
brady-arrhythmias and asystoles longer than 3 seconds
from associated autonomic dysfunction and chronic hyp-
oxia will require a pacemaker implantation. For patients
without cardiac abnormalities, 24-72-hour Holter ECG
monitoring is recommended once a year to estimate heart
rhythm and exclude brady-arrhythmias, long sinus pauses
and asystoles.
The mode of permanent cardiac pacing depends on
individual patient characteristics. The system may have
either a single or dual chamber leads with endocardial
or epicardial pacing. Single chamber devices have one
implanted pacing lead in right atrium or ventricle, anddual chamber, two implanted pacing leads (one in the
right ventricle and one in the right atrium). These leads
subsequently are connected to a pacemaker placed sub-
cutaneously or sub muscles in the chest.
Epicardial pacing is preferred in neonates and children
with a weight of <15 -20 kg. It is also used in some chil-
dren after cardiac surgery and in those without appropriate
venous accesses to the heart.
The longevity of cardiac pacing is limited to around
6–8 years. Epicardial lead implantation by thoracotomy
can lead to postpericardiotomy syndrome, some patients
need pericardiocentesis to remove pericardial fluid and to
prevent cardiac tamponade which may be a life threaten-
ing complication. Complications occur in both epicardial
and endocardial pacing. Lead related complications in-
clude fracture, failure of the wire insulation, dislocation,
malposition and diaphragmatic stimulation. Lead-related
problems such as increased pacing thresholds and de-
creased impedance can cause premature battery depletion.
Cardiac arrhythmias may occur after pacemaker implant-
ation. Pacemaker infections and progressive heart failure
can be life-threatening problems. Local pocket-related
complications, such as haematoma and venous throm-
bosis may also be observed post pacemaker implantation.
Failed leads need to be replaced. Transvenous extraction
of non-functional, abandoned endocardial leads is a diffi-
cult and dangerous procedure. Current practice is to re-
move damaged leads.
Permanent cardiac pacing helps to normalise heart
rhythm and improve quality of life, but long-term pacing
is limited by the battery depletion and by complications
(mainly lead failure).
Life as an adult
Linda MIDDLETON. Parent and UK CCHS Support
Network
Ryan, my son, a young adult, living in UK, has CCHS.
He has agreed to me sharing his experience of life as an
adult. Some of the issues these young adults face are com-
mon to those of any young person, while others are frus-
trations which are intensified by their medical condition.
After finishing school, Ryan attended a mainstream col-
lege and lived at home. He did not want to attend a college
for children with special medical needs. Had he wanted to
move away from home, we would have supported him,
although this would have been difficult. Colleges and
universities expect students to be independent in all
areas of their lives, and provide much less support than
schools. Student accommodation is not usually appro-
priate for people with medical equipment and who need
overnight care.
The medical world is not ready for adults with CCHS
in UK. Many local hospitals, including our own, are not
familiar with CCHS and ventilators. This makes the
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vices, difficult. In contrast to paediatric services, many adult
hospital services may not understand the need for ventila-
tors at night and for full physiological sleep studies. Under
children’s services we were used to full physiological sleep
studies including recording of oxygen saturation, pulse
waveforms, breathing movements, transcutaneous and end-
tidal CO2, ECG and heart rate, airway pressures and video.
Although Ryan always wears a medic alert bracelet, we
would want a family member present, if he was admitted to
hospital in an emergency. Families need to search for hos-
pital centres that understand the condition and can provide
appropriate support.
Public transport, driving a car and traveling present ob-
stacles for these adults; some are refused a driving license.
Buses and trains do not provide consistent facilities, secur-
ity procedures at airports and transporting medical equip-
ment make journeys, very challenging. Although Ryan is
now 22 years old, we still take him to and from work (due
to unreliable local transport) and collect him from social
outings because we feel he is extremely vulnerable.
In his late teens Ryan preferred to go on holiday
with his older brother, rather than with his parents.
He will decline to go on holiday with friends. Ryan has
never stayed away from home overnight without either
a member of his family or a carer. He does not want
his friends to know he needs a carer to look after him
at night. He does not believe his friends would think
any less of him, if they knew. However, taking an extra
person on holiday to support him at night would be
too traumatic.
Ryan is reluctant to tell friends and work colleagues
about his condition for fear of being seen as different.
He only tells people what they need to know. From a
parent’s perspective, the more people who know what to
look out for if he becomes unwell and the safer Ryan is.
Ryan’s standpoint is different: he is a well person until
he goes to sleep and needs a ventilator. As he is with his
friends when he is awake, they don’t need to know any-
more. The embarrassment and trauma of telling others
of their condition is illustrated by a young male CCHS
adult who is considering finishing his relationship with
his girlfriend, because he does not want to tell her about
his medical condition.
Sport is Ryan’s biggest hobby. Football and tennis are his
favourites. He was chosen to play in a football match. Once
the club knew about his condition, he was excluded. Ryan
regrets sharing the information and sees the club’s decision
as discrimination. He has left the club and will not join an-
other one.
Ryan understands the risks of taking drugs and alcohol
and abstains from them completely. However, there is
always the risk of either direct or indirect peer pressure
from his social group, CCHS acquaintances who drinkand family members. His friends accept that he has a
medical condition that prevents him from drinking al-
cohol and do not pressurize him to join in.
Ryan has a job he enjoys. When applying for the post,
he revealed his medical condition only after he was offered
the position for fear of discrimination. Travel to work can
be problematic and access-to-work schemes have limited
funding. CCHS adults consider them ‘normal’ and do not
like applying for funding for physically disabled people.
CCHS adults are disadvantaged in the workplace and miss
career opportunities because it is difficult for them to
work away from home temporarily or permanently.
Independent living is a challenge for these young people.
When Ryan leaves home, he will live initially close to his
family and have overnight carers. The health authority has
agreed to fund 9 hours per night, 7 days a week; this is not
a flexible arrangement. There is no daytime care provision.
If he needs to sleep during the day due to illness or for
other reasons, he would either have to move back home
temporarily, or have a family member move in. A service
dog would provide additional support for Ryan. However,
at present these facilities are not available in UK.
To live independently CCHS adults need to take respon-
sibility for their medical condition. However, parents often
overprotect their child and manage their condition for
them. For example, Ryan has limited knowledge of how
his medical equipment works and his full medical history.
At medical appointments, I speak, with his permission, on
his behalf. Parents are afraid that their children cannot
look after themselves or may take decision that put their
lives at risk.
Other issues of independent living include looking after
their finances, their household and making decisions
about having children. Ryan has a 50% chance of transmit-
ting CCHS to his offspring. He hopes to have children and
says he can cope with a child with CCHS. This is not the
case for all CCHS adults. Some do not want children for
fear of transmitting the condition to their offspring.
Ryan acknowledges that as his parents get older, other
support networks will be required. Where will this sup-
port come from? His older brother does not live near-by,
and it raises the question whether siblings have an obli-
gation to each other?
Ryan does lead a full and happy life, despite all its frus-
trations. Medical technology is only a small part of his
life - other technology, as in the X-box, is a major part
of his life! He has a job he loves and an active social life
which causes us, his parents, a great deal of stress, but
we wouldn’t have it any other way.The impact of CCHS on families
Francesco MORANDI, MD. Ospedale Sacra Famiglia,
Erba , Italy
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tionships to enable them to develop and grow. These
growth- promoting activities are provided by a child’s
continuous “serve and return” interaction with a parent
or caregiver. They provide experiences that are unique to
that child, and stimulate its development [87]. It starts in
the first hours of the newborn’s life, when a child is placed
in the mother’s arms, and continues through to adulthood.
In the past, this cooperative nurturing was performed pri-
marily by the mother within a ‘traditional family’ group
with a father and the child’s siblings. Today, effective care
is also provided in other social contexts, with around 20%
of infants now raised by single parents or within same sex
partnerships [88].
The care provided for a child in the first year of life is
particularly important. At this time, there is rapid forma-
tion and development of neural connections within the
brain that will subsequently impact the child’s learning
capabilities, adaptive behaviour and life-long physical and
mental health. These development changes are influenced
not only by the genetic predisposition of the child, but also
by the child’s personal and social experiences, and its early
physical environment [89].
In the first year of life, a child with CCHS may encounter
an unfavourable physical environment and stressful rela-
tionships with family and carers. The child may experience
severe pain and spend considerable time in intensive care
without parental contact. These traumatic circumstances
may disrupt the child’s physical and mental development if
appropriate support and nurturing is lacking.
The family of a child with CCHS also experiences emo-
tional upheaval. The parents of a 6 month old child with
CCHS found the situation overwhelming saying: “We (as a
family) have ceased to live.” Stress in these circumstances
affects individuals differently. A Parenting Stress Index
questionnaire completed by 16 couples, each with a
child with CCHS, revealed that the level of stress was
near to the risk threshold for the mother but not for
the father [90].
Parents’ distress may be compounded by the reactions
of those around them. To illustrate this, one parent re-
ported “I saw the panic in the eyes of the health care
professionals when my child was diagnosed with CCHS.”
They then had to endure their son being labelled by so-
ciety as ‘that child with Ondine’s curse’ [90].
As parents adapt and reorganise their lives to a child
with CCHS, their reactions may evolve through some, or
all, of these phases: initial shock, then denial, sadness
and anger, before accepting their situation. This process
of adaptation is illustrated in the following quotes from
parents: “If I had known before how difficult, demand-
ing, time-consuming and exhausting it would be to have
my child on a ventilator, I would have never agreed to
bring her home”. Over time the parents were proud ofher achievement, “Today, after 10 years, we are proud of
our Maria despite some sleepless nights, it is a joy for us
to see her run, swim, jump, play football (her favourite
sport), just like her peers“ [90]. By understanding parents’
reactions, healthcare professionals are better equipped to
respond to parents’ emotional needs and provide appro-
priate support [91].
The impact of CCHS on families and caregivers has
not been widely studied. Carers are reported to have low
levels of psychological stress, to be highly motivated and
to cope well with the demands of looking after a child
with CCHS [65,92]. They are also able to safely use all
forms of invasive and non-invasive respiratory devices in
the home [93]. However, the intensive care and attention
the child requires may lead to a high level of marital dis-
cord [65,94] and, to mothers having little time to look
after their own health [95].
Support groups can help parents and children cope
with their unique problems [96,97]. Using the WHO's
International Classification of Functioning, Disability and
Health, Children and Youth version (ICF-CY), trained
health professionals undertook telephone interviews with
one parent of each of 26 CCHS children, aged 1.5-17.5 years.
The results showed that support by the immediate fam-
ily was the most important factor in facilitating the de-
velopment of the child; while that provided by the
extended family, healthcare professionals and social ser-
vices had an ambiguous effect, sometimes facilitating,
at other times inhibiting the development of the child.
Healthcare professionals should be more responsive to
the needs of these families and tailor developmental
tasks to the functional abilities of the child [96]. This
individualised case management approach has been used
to deliver effective clinical care pathways in other chronic
conditions, and should be adopted in CCHS [98]. Rare dis-
eases such as CCHS have considerable implications for
society. The cumulative burden of rare diseases in the
EU is significant, affecting as many as 30 million people.
Many parents have no choice but to become full-time
carers [99].
The true cost of CCHS to families is not known. A com-
prehensive epidemiologic survey of 196 patients with a
CCHS child has revealed that the disease causes signifi-
cant financial and psychosocial burden for these families
[9]. However, the care which is unpaid is also considerable,
life-long and largely unrecognised or acknowledged by
society, and as a result rarely evaluated in financial
terms [88,100].
More research is required to understand the impact of
CCHS on the family and the support required from
health and social services. Here the EU consortium may
have an important role. Training programmes in the med-
ical humanities should be integrated into medical teaching
in universities. This will lead to a more holistic approach
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should be family-centred, and interventions aimed at
improving psychosocial outcomes for these critically- ill
children. Programmes, such as NIDCAP (Newborn Indi-
vidualized Developmental Care and Assessment Program),
MITP (Mother-Infant Transaction Programme), COPE
(Creating Opportunities for Parent Empowerment) and
others, should be actively encouraged as they help im-
prove families’ quality of life and assist parents in devel-
oping the lives of their children.
Future goals in the management of CCHS
Giancarlo Ottonello. via Gerolamo Gaslini, Genova,
Italy
CCHS is a rare disorder characterized by a defective
response of the autonomic nervous system to hypoxia
and hypercapnia. Data from a French epidemiological
study has confirmed that CCHS is associated with muta-
tions in the PHOX2B gene [13]. Currently, there are no
treatments that alter the natural course of the disease. In
other rare genetic disorders, such Haemophilia B and
Cystic Fibrosis, promising treatment modalities have
emerged from an understanding of the underlying gen-
etic basis for these conditions [101,102].
In CCHS, there is progress in identifying candidate
drug treatments that modulate the expression of the
PHOX2B gene. Several in vitro studies have investigated
drugs that promote the clearance of mutant proteins
which result from the expression of the PHOX2B gene
with an expanded polyalanine region [32,103-105]. Animal
studies are now required to screen these compounds
before clinical trials in CCHS patients. A recent clinical
observation has documented a positive response in CCHS
patients taking the progestin, desogestrel [106]. This has
prompted a clinical study of the efficacy of desogestrel in
CCHS patients and the results are expected in the next
24 months [107].
Recent studies on the genetic transmission of the CCHS
have identified PHOX2B mutant alleles that are transmit-
ted to offspring from asymptomatic parents. Around 10%
of these unaffected parents show somatic mosaicism for
the alanine expansion mutation seen in their children [40].
As asymptomatic mutation carriers are at risk of develop-
ing alveolar hyperventilation, and bearing a child with
CCHS, genetic screening may now be appropriate in these
individuals [108].
Although diagnosis of CCHS has improved [13] in some
countries there is no consensus on the most appropriate
criteria for diagnosis and management of the disease
[109]. Earlier diagnosis, together with access to a respira-
tory ventilator, is required to prevent neurocognitive dam-
age and fatal events in these children. Clinicians need
more training to recognise CCHS and tools developed
to assist with early diagnosis. Sharing information throughthe dissemination of case reports [110,111] and close
collaboration and development of a centralised database on
respiratory diseases of childhood, may lead to a better
insight into these conditions [112]. A recent compre-
hensive epidemiological study, which surveyed the medical
and psycho-social complexities of CCHS, found significant
deficiencies in the routine evaluation and management of
CCHS children [92]. This points to the urgent need for
the implementation of guidelines and statements [10,113].
More work is needed to expand our knowledge on the
neurological development of CCHS patients. Few papers
address this aspect of the disease. A study of the neuro-
cognitive functioning in school-aged children suggests that
CCHS may confer risk for adverse neurocognitive outcome
[114]. Children and adolescents with CCHS may also have
functional and social difficulties in coping with the activ-
ities of every day life, which may lead to learning difficulties
at school [96]. Healthcare, community and home support
is therefore required to improve and nurture the social and
intellectual development of these children.
Mechanical ventilators are pivotal to the survival of
most children with CCHS. There is a pressing need for
healthcare professionals to improve their knowledge of the
technical performance of current intensive care and non-
invasive home mechanical ventilators. Trigger delay and
work load, pressurisation capabilities and cycling profile
all impact the performance of these devices. Healthcare
staff and patients need to be instructed, on the different
characteristics of ventilators and, the precautions neces-
sary for optimal use [115-117]. Development of devices
that enhance patient-ventilator synchrony will also help to
improve the respiratory assistance required by patients.
Nasal masks for non-invasive, long-term positive pressure
ventilation need to be adapted or changed as the child
grows to avoid discomfort, skin injury and, to accom-
modate structural development of the face [118]. Angle
Class III malocclusion and severe maxillary hypoplasia
treated using devices such as Frankel III orthodontic
method [119] and Delaire masks [120] or by LeFort sur-
gery [121] require protocols that standardise procedures
to improve outcomes.
Diaphragmatic pacing of the phrenic nerve or of the
diaphragm muscle, can improve ventilation and eliminate
the need for continuous positive pressure ventilation sup-
port. The safety of direct diaphragm stimulation has been
demonstrated in a number of respiratory conditions,
including a patient with CCHS [77,122]. Obstructive sleep
apnoea, arising from phrenic pacing, can be treated by
hypoglossal nerve stimulation or a mandible advancement
splint [123,124]. This will improve the child’s quality of
sleep and as a consequence, improve neuro-behavioural
function [125].
CCHS is a condition which requires a multidisciplinary
approach at both hospital and community levels. Within
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nated care across multiple hospital departments: car-
diac, oncology, radiology, endocrinology, neurology and
surgical units. Laboratory support for genetic testing,
and psychosocial counselling services are also required.
In addition, specialised diagnostic screening and surgery
equipment is required for the treatment of associated con-
ditions, such as Hirschsprung’s disease [126,127].
Home, community and hospital care support must be
integrated: patients should have a follow-up program on
discharge from hospital, access to emergency care for treat-
ment and, for respiratory devices, as well as, access to re-
habilitation units, psychosocial counselling, home support
nurses, school nurses, patient associations and self-support
groups. Respiratory care is needed to provide the oppor-
tunity for carers to plan holidays and social events.
Home care plays a crucial role in the well-being of pa-
tients. Technology is likely to play an increasing role.
Breathing parameters recorded at home are comparable
with those taken in hospital [128]. The future is likely
to involve a combination of home monitoring and tele-
medicine [129]. Helping CCHS adults to live independ-
ently of their families, are initiatives currently under
investigation by the Italian [130] and French Families
Associations [131]. One study has reported a relationship
between the depressive state of a carer of ventilator-
assisted children and the number of hours a week a nurse
is present to provide support [132]. Home care nursing
support, in particular night nursing, appears to be import-
ant for the health and well-being of care givers of children
with CCHS. However, this support is unlikely to be univer-
sally available. Recent research reveals, that even in a
developed country, there is a large gap between family
members' expectations and provisions of community health
care services. Proposals to limit the extremely costly
provision of home mechanical ventilation may trigger
new ethical dilemmas that should be studied [133].
While there is progress in understanding the genetic
basis of the disease, there remain significant challenges
in correlating the genotype-phenotype characteristic of
the disease, developing effective treatments, co-ordinating
care across multidisciplinary healthcare teams and im-
proving ventilator equipment for these patients. Further
genetic studies are required to improve diagnosis, charac-
terise the disease and its outcomes.
Endnotes
aHeLa cells are a cell type in an immortal cell line used
in scientific research, named after the patient’s name
Henrietta Lacks.
bThe recruitment for this open-label, non-randomized
and prospective study ended in September 2013. Of the
expected 12, only five patients were included. Only very
preliminary results are currently available. The ventilatoryresponse to CO2 did not recover in three patients who
received desogestrel for the first time in their life. This
response deteriorated slightly in two other patients who
were previously treated with desogestrel or levonorgestrel
when they stopped taking these drugs for the purpose
of the study. At this stage, no simple conclusion can be
drawn and further analyses are needed. A research pro-
gram is currently conducted on animal models to better
understand the effect of progestin and desogestrel on
the control of breathing. It is of highest importance to
recall that desogestrel and progestin should not be pre-
scribed to CCHS patients with the goal of restoring their
ventilatory response to CO2.
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